BR112018001116A2 - inibidor de fosfodiesterase 4 (pde4) para o tratamento de nefropatia diabética - Google Patents

inibidor de fosfodiesterase 4 (pde4) para o tratamento de nefropatia diabética

Info

Publication number
BR112018001116A2
BR112018001116A2 BR112018001116-9A BR112018001116A BR112018001116A2 BR 112018001116 A2 BR112018001116 A2 BR 112018001116A2 BR 112018001116 A BR112018001116 A BR 112018001116A BR 112018001116 A2 BR112018001116 A2 BR 112018001116A2
Authority
BR
Brazil
Prior art keywords
inhibitor
phosphodiesterase
treatment
diabetic nephropathy
pde4
Prior art date
Application number
BR112018001116-9A
Other languages
English (en)
Inventor
Hanauer Guido
Vollert Stephanie
Hazama Masatoshi
Matsuo Takanori
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of BR112018001116A2 publication Critical patent/BR112018001116A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se ao tratamento de nefropatia diabética com a) um inibidor de fosfodiesterase 4, b) uma combinação de um inibidor de fosfodiesterase 4 com um antagonista do receptor de angiotensina ii at1 ou c) uma combinação de um inibidor de fosfodiesterase 4 com um inibidor de enzima que converte angiotensina.
BR112018001116-9A 2015-07-29 2016-07-28 inibidor de fosfodiesterase 4 (pde4) para o tratamento de nefropatia diabética BR112018001116A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562198213P 2015-07-29 2015-07-29
US62/198,213 2015-07-29
PCT/EP2016/067968 WO2017017165A1 (en) 2015-07-29 2016-07-28 Pde4 inhibitor for the treatment of diabetic nephropathy

Publications (1)

Publication Number Publication Date
BR112018001116A2 true BR112018001116A2 (pt) 2018-09-11

Family

ID=56551407

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001116-9A BR112018001116A2 (pt) 2015-07-29 2016-07-28 inibidor de fosfodiesterase 4 (pde4) para o tratamento de nefropatia diabética

Country Status (9)

Country Link
US (1) US20200179369A1 (pt)
EP (1) EP3328381A1 (pt)
JP (1) JP2018521077A (pt)
CN (1) CN108135886A (pt)
BR (1) BR112018001116A2 (pt)
CA (1) CA2992796A1 (pt)
EA (1) EA201890346A1 (pt)
MA (1) MA42519A (pt)
WO (1) WO2017017165A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110099686B (zh) * 2016-08-26 2022-04-15 武田药品工业株式会社 非酒精性脂肪性肝病的治疗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2464561A1 (en) * 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
RS52916B (en) * 2004-03-03 2014-02-28 Takeda Gmbh NEW HYDROXY-6-HETEROARYLPHENANTRIDINES AND THEIR USE AS PDE4 INHIBITORS

Also Published As

Publication number Publication date
JP2018521077A (ja) 2018-08-02
MA42519A (fr) 2018-06-06
EA201890346A1 (ru) 2018-08-31
EP3328381A1 (en) 2018-06-06
US20200179369A1 (en) 2020-06-11
CN108135886A (zh) 2018-06-08
WO2017017165A1 (en) 2017-02-02
CA2992796A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
CL2017003142A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001368A1 (es) Composiciones que comprenden cepas bacterianas
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
MD3204025T2 (ro) Compoziții care conțin tulpini bacteriene
TR201820333T4 (tr) Bakteri Suşları İçeren Bileşimler
BR112018004620A2 (pt) moduladores da expressão de kras
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA201790998A1 (ru) Иммуннорегуляторные агенты
BR112018011709A2 (pt) inibidores bicíclicos de pad4
AU2016366310A8 (en) Improved apelin receptor (APJ) agonists and uses thereof
EA201691916A1 (ru) Биарильные ингибиторы киназы
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
BR112017000024A2 (pt) composição para tratamento de tecidos que compreende uma nanoemulsão polimérica de aminossiloxano
MA40998A (fr) Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
BR112015023207A8 (pt) composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
EA201990159A1 (ru) Биарилметильные гетероциклы
ZA201701131B (en) Novel 2,5-substituted pyrimidines as pde4 inhibitors
BR112017017970A2 (pt) composição de fragrância e combinação de fragrâncias
MX2017005249A (es) Compuestos para usarse en el tratamiento antihelmintico.
CL2015002113A1 (es) Compuestos de azetidinloxifenilpirrolidina
BR112018005331A2 (pt) inibidores de pcna

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]